Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

ADC demonstrates meaningful survival data for HER2 cancers

3
SHARES

Topline data from a Phase II trial signify a significant step forward for ENHERTU® (trastuzumab deruxtecan) in its potential to provide a new option in HER2 expressing cancers.

ADC demonstrates meaningful survival data for HER2 cancers

ENHERTU® (trastuzumab deruxtecan) has demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in topline results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The data was for previously treated patients across multiple HER2 expressing advanced solid tumours, two secondary endpoints.

ENHERTU, a HER2 directed antibody drug conjugate (ADC) anti-cancer treatment, is being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.

Topline data from the primary analysis

In the primary analysis, ENHERTU also continued to show durable responses based on objective response rate (ORR), the trial’s primary endpoint, and duration of response (DoR), a secondary endpoint. This reinforces results from an interim analysis of the trial that were presented at the 2023 American Society of Oncology (ASCO) annual meeting.

The Phase II trial is evaluating the efficacy and safety of the treatment in patients with previously treated locally advanced, unresectable or metastatic HER2 expressing solid tumours not eligible for curative therapy. These cancers include biliary tract, bladder, cervical, endometrial, ovarian and pancreatic.

These data will be presented at an upcoming medical meeting and will support ongoing discussions with global health authorities.

“The overall survival demonstrated by ENHERTU in these patients is a significant step forward in the potential to advance current standards of care and offer new options for patients with HER2 expressing cancers”

Based on these updated results: “The overall survival demonstrated by ENHERTU in these patients is a significant step forward in the potential to advance current standards of care and offer new options for patients with HER2 expressing cancers,” according to Dr Mark Rutstein, Global Head of Oncology Development at Daiichi Sankyo.

“With a high unmet need in these cancers, we are working with health authorities to bring ENHERTU to patients with HER2 expressing cancers that could potentially benefit from this medicine as quickly as possible,” added Dr Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer for AstraZeneca.

What is ENHERTU’s design?

ENHERTU consists of a HER2 monoclonal antibody (mAb) attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker.

Enhertu approved in EU for HER2-low breast cancer

Share via
Share via